Divergent Planning LLC Purchases Shares of 93,497 Kenvue Inc. $KVUE

Divergent Planning LLC purchased a new position in shares of Kenvue Inc. (NYSE:KVUE) during the 2nd quarter, Holdings Channel.com reports. The fund purchased 93,497 shares of the company’s stock, valued at approximately $1,957,000.

Several other institutional investors and hedge funds have also modified their holdings of the stock. Pittenger & Anderson Inc. purchased a new stake in shares of Kenvue in the first quarter worth about $30,000. Trust Co. of Vermont raised its position in Kenvue by 266.8% during the second quarter. Trust Co. of Vermont now owns 1,581 shares of the company’s stock valued at $33,000 after acquiring an additional 1,150 shares in the last quarter. TruNorth Capital Management LLC acquired a new position in Kenvue in the first quarter valued at approximately $36,000. Truvestments Capital LLC purchased a new stake in Kenvue in the 1st quarter worth approximately $37,000. Finally, Clal Insurance Enterprises Holdings Ltd grew its stake in shares of Kenvue by 378.5% during the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 1,627 shares of the company’s stock worth $39,000 after purchasing an additional 1,287 shares during the period. Institutional investors and hedge funds own 97.64% of the company’s stock.

Kenvue Stock Down 2.2%

KVUE opened at $14.96 on Tuesday. The company has a market cap of $28.71 billion, a PE ratio of 20.22, a price-to-earnings-growth ratio of 2.20 and a beta of 0.72. Kenvue Inc. has a twelve month low of $14.05 and a twelve month high of $25.17. The company has a 50-day moving average price of $18.42 and a 200 day moving average price of $20.97. The company has a quick ratio of 0.68, a current ratio of 0.98 and a debt-to-equity ratio of 0.66.

Kenvue (NYSE:KVUE) last posted its quarterly earnings data on Thursday, August 7th. The company reported $0.29 EPS for the quarter, topping the consensus estimate of $0.28 by $0.01. Kenvue had a return on equity of 20.06% and a net margin of 9.37%.The company had revenue of $3.84 billion during the quarter, compared to analyst estimates of $3.94 billion. During the same period in the previous year, the business earned $0.32 EPS. Kenvue’s quarterly revenue was down 4.0% on a year-over-year basis. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. Sell-side analysts expect that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, August 27th. Investors of record on Wednesday, August 13th were paid a $0.2075 dividend. The ex-dividend date of this dividend was Wednesday, August 13th. This represents a $0.83 annualized dividend and a yield of 5.5%. This is an increase from Kenvue’s previous quarterly dividend of $0.21. Kenvue’s dividend payout ratio is currently 112.16%.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on KVUE shares. Rothschild & Co Redburn upgraded shares of Kenvue from a “neutral” rating to a “buy” rating and decreased their target price for the company from $22.50 to $22.00 in a research note on Friday, September 26th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Kenvue in a report on Tuesday, October 14th. Rothschild Redb upgraded shares of Kenvue from a “hold” rating to a “strong-buy” rating in a research report on Friday, September 26th. Redburn Partners set a $22.00 target price on Kenvue in a research report on Friday, September 26th. Finally, JPMorgan Chase & Co. cut their price target on Kenvue from $24.00 to $21.00 and set an “overweight” rating for the company in a research note on Friday, October 10th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, nine have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $21.18.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.